6.
Chelakkot C, Chelakkot V, Shin Y, Song K
. Modulating Glycolysis to Improve Cancer Therapy. Int J Mol Sci. 2023; 24(3).
PMC: 9916680.
DOI: 10.3390/ijms24032606.
View
7.
Moreno-Sanchez R, Saavedra E, Gallardo-Perez J, Rumjanek F, Rodriguez-Enriquez S
. Understanding the cancer cell phenotype beyond the limitations of current omics analyses. FEBS J. 2015; 283(1):54-73.
DOI: 10.1111/febs.13535.
View
8.
Cantuaria G, Fagotti A, Ferrandina G, Magalhaes A, Nadji M, Angioli R
. GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer. 2001; 92(5):1144-50.
DOI: 10.1002/1097-0142(20010901)92:5<1144::aid-cncr1432>3.0.co;2-t.
View
9.
Koukourakis M, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, Gatter K
. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer. 2003; 89(5):877-85.
PMC: 2394471.
DOI: 10.1038/sj.bjc.6601205.
View
10.
Koukourakis M, Giatromanolaki A, Sivridis E, Gatter K, Harris A
. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group. J Clin Oncol. 2006; 24(26):4301-8.
DOI: 10.1200/JCO.2006.05.9501.
View
11.
Altenberg B, Greulich K
. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics. 2004; 84(6):1014-20.
DOI: 10.1016/j.ygeno.2004.08.010.
View
12.
Goldman N, Katz E, Glenn A, Weldon R, Jones J, Lynch U
. GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma. Mod Pathol. 2006; 19(11):1429-36.
DOI: 10.1038/modpathol.3800656.
View
13.
Liu G, Zhu J, Yu M, Cai C, Zhou Y, Yu M
. Glutamate dehydrogenase is a novel prognostic marker and predicts metastases in colorectal cancer patients. J Transl Med. 2015; 13:144.
PMC: 4490642.
DOI: 10.1186/s12967-015-0500-6.
View
14.
He X, Wu C, Cui Y, Zhu H, Gao Z, Li B
. The aldehyde group of gossypol induces mitochondrial apoptosis via ROS-SIRT1-p53-PUMA pathway in male germline stem cell. Oncotarget. 2017; 8(59):100128-100140.
PMC: 5725007.
DOI: 10.18632/oncotarget.22044.
View
15.
Sun Z, Chen X, Wang G, Li L, Fu G, Kuruc M
. Identification of functional metabolic biomarkers from lung cancer patient serum using PEP technology. Biomark Res. 2016; 4:11.
PMC: 4888258.
DOI: 10.1186/s40364-016-0065-4.
View
16.
Zhu A, Lee D, Shim H
. Metabolic positron emission tomography imaging in cancer detection and therapy response. Semin Oncol. 2011; 38(1):55-69.
PMC: 3075495.
DOI: 10.1053/j.seminoncol.2010.11.012.
View
17.
Pavlidis N, Briasoulis E, Hainsworth J, Greco F
. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003; 39(14):1990-2005.
DOI: 10.1016/s0959-8049(03)00547-1.
View
18.
Podoloff D
. PET/CT and occult primary tumors. J Natl Compr Canc Netw. 2009; 7(3):239-44.
DOI: 10.6004/jnccn.2009.0019.
View
19.
Ozeki Y, Abe Y, Kita H, Tamura K, Sakata I, Ishida J
. A case of primary lung cancer lesion demonstrated by F-18 FDG positron emission tomography/computed tomography (PET/CT) one year after the detection of metastatic brain tumor. Oncol Lett. 2012; 2(4):621-623.
PMC: 3406449.
DOI: 10.3892/ol.2011.318.
View
20.
Landau B, Laszlo J, STENGLE J, BURK D
. Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-D-glucose. J Natl Cancer Inst. 1958; 21(3):485-94.
View